Kezar Life Sciences, Inc. (KZR)
7.29
0.00 (0.00%)
USD |
NASDAQ |
Oct 02, 16:00
Kezar Life Sciences Max Drawdown (5Y) : 98.04% for Sept. 30, 2026
Max Drawdown (5Y) Chart
Historical Max Drawdown (5Y) Data
| Date | Value |
|---|---|
| September 30, 2026 | 98.04% |
| August 31, 2026 | 98.04% |
| July 31, 2026 | 98.04% |
| June 30, 2026 | 98.04% |
| May 31, 2026 | 98.04% |
| April 30, 2026 | 98.04% |
| March 31, 2026 | 98.04% |
| February 28, 2026 | 98.04% |
| January 31, 2026 | 98.04% |
| December 31, 2025 | 98.04% |
| November 30, 2025 | 98.04% |
| October 31, 2025 | 98.04% |
| September 30, 2025 | 98.04% |
| August 31, 2025 | 97.91% |
| July 31, 2025 | 97.91% |
| June 30, 2025 | 97.91% |
| May 31, 2025 | 97.91% |
| April 30, 2025 | 97.85% |
| March 31, 2025 | 97.82% |
| February 28, 2025 | 97.82% |
| January 31, 2025 | 97.82% |
| December 31, 2024 | 97.82% |
| November 30, 2024 | 97.82% |
| October 31, 2024 | 97.82% |
| September 30, 2024 | 97.82% |
| Date | Value |
|---|---|
| August 31, 2024 | 97.82% |
| July 31, 2024 | 97.82% |
| June 30, 2024 | 97.82% |
| May 31, 2024 | 97.82% |
| April 30, 2024 | 97.82% |
| March 31, 2024 | 97.82% |
| February 29, 2024 | 97.82% |
| January 31, 2024 | 97.82% |
| December 31, 2023 | 97.82% |
| November 30, 2023 | 97.82% |
| October 31, 2023 | 97.81% |
| September 30, 2023 | 96.72% |
| August 31, 2023 | 96.11% |
| July 31, 2023 | 93.50% |
| June 30, 2023 | 92.98% |
| May 31, 2023 | 92.89% |
| April 30, 2023 | 92.89% |
| March 31, 2023 | 92.40% |
| February 28, 2023 | 92.40% |
| January 31, 2023 | 92.40% |
| December 31, 2022 | 92.40% |
| November 30, 2022 | 92.40% |
| October 31, 2022 | 92.40% |
| September 30, 2022 | 92.40% |
| August 31, 2022 | 92.40% |
Max Drawdown Definition
Max drawdown is an indicator of the risk of a portfolio chosen based on a certain strategy. It measures the largest single drop from peak to bottom in the value of a portfolio before a new peak is achieved.
Max Drawdown (5Y) Range, Past 5 Years
--
Minimum
--
Maximum
--
Average
--
Median
Max Drawdown (5Y) Benchmarks
| NovelStem International Corp. | 98.06% |
| Brainstorm Cell Therapeutics, Inc. | 46.35% |
| Summit Therapeutics, Inc. | 95.40% |
| Protara Therapeutics, Inc. | 99.25% |
| Clene, Inc. | 99.27% |
Max Drawdown (5Y) Related Metrics
| Alpha (5Y) | -46.82 |
| Beta (5Y) | 0.4022 |
| Annualized Standard Deviation of Monthly Returns (5Y Lookback) | 80.80% |
| Historical Sharpe Ratio (5Y) | -0.5297 |
| Historical Sortino (5Y) | -0.8966 |
| Monthly Value at Risk (VaR) 5% (5Y Lookback) | 34.32% |